n-formyl-13-dihydrocarminomycin has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abshire, CM; Galeas-Pena, M; Harris, NR; Horton, AC; Katakam, PVG; Kilanowski-Doroh, I; Lindsey, SH; Mcnally, AB; Ogola, BO; Prieto, MC; Reverte, V; Rosales, CB; Sakamuri, SSVP; Sure, VN; Visniauskas, B; Zimmerman, M | 1 |
| Anaya, BJ; Ballesteros, MP; Cerda, JR; D'Atri, RM; Kara, A; Luciano, FC; Ruiz, HK; Serrano, DR; Yuste, I | 1 |
2 other study(ies) available for n-formyl-13-dihydrocarminomycin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
High-plasma soluble prorenin receptor is associated with vascular damage in male, but not female, mice fed a high-fat diet.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diet, High-Fat; Female; Hypertension; Male; Mice; Mice, Inbred C57BL; Prorenin Receptor; Reactive Oxygen Species; Receptors, Cell Surface; Renin; Renin-Angiotensin System; Vacuolar Proton-Translocating ATPases | 2023 |
Engineering of 3D printed personalized polypills for the treatment of the metabolic syndrome.
Topics: Diabetes Mellitus, Type 2; Drug Liberation; Humans; Metabolic Syndrome; Printing, Three-Dimensional; Solubility; Tablets; Technology, Pharmaceutical | 2023 |